G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: G-CSF may prevent or control neutropenia caused by first-line therapy in patients with metastatic colorectal cancer.
PURPOSE: This phase II trial is studying how well G-CSF works in preventing neutropenia during first-line treatment with chemotherapy and bevacizumab in patients with metastatic colorectal cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Colorectal Cancer |
Biological: bevacizumab Biological: filgrastim Drug: fluorouracil Drug: irinotecan hydrochloride Drug: leucovorin calcium |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Supportive Care |
| Official Title: | Phase II, Multicenter Study Evaluating G-CSF as Primary Prophylaxis for Neutropenia Associated With First-Line Chemotherapy Regimen FOLFIRI and Bevacizumab in Patients With Metastatic Colorectal Cancer Who Are Homozygous for UGT1A1*28 Polymorphism, the Promoter of the Gene Encoding for the Enzyme UGT1A1 |
- Rate of neutropenia grade 4 or fever
- Toxicities by NCI-CTC v. 2.0
- Objective response at 6 months by RECIST
- Tolerance (except neutropenia) by NCI-CTC v. 2.0
- Progression-free survival
- Overall survival
- Time to treatment failure
| Estimated Enrollment: | 30 |
OBJECTIVES:
Primary
- Determine if primary prophylaxis comprising filgrastim (G-CSF) makes it possible to obtain neutropenia lower than grade 4 or a 30% decrease in fever in patients with metastatic colorectal cancer receiving first-line FOLFIRI and bevacizumab and who are homozygous for allele UGT1A1*28 (genotype 7/7), a promoter of the gene coding for enzyme UGT1A1.
Secondary
- Evaluate the objective response rate at 6 months of treatment with FOLFIRI and bevacizumab according to RECIST criteria.
- Evaluate the toxicity (excluding neutropenia) of FOLFIRI and bevacizumab according to NCI-CTC v. 2.0.
- Determine progression-free and overall survival.
- Determine the time to treatment failure.
OUTLINE: This is a multicenter study.
Patients receive bevacizumab IV over 30-90 minutes, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1. Patients also receive filgrastim (G-CSF) subcutaneously on days 5-11. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed every 2-3 months for up to 5 years.
Eligibility| Ages Eligible for Study: | 18 Years to 74 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Inclusion criteria:
Histologically confirmed adenocarcinoma of the colon or rectum
- Metastatic disease
- Not surgically curable
- Homozygous for allele UGT1A1*28, the promoter of the gene coding for UGT1A1 (genotype 7/7)
- Measurable and/or evaluable disease
Exclusion criteria:
- Original tumor not removed
- CNS metastases
- Secondary localized cerebral tumors
PATIENT CHARACTERISTICS:
Inclusion criteria:
- WHO performance status 0-2
- ANC ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 9 g/dL
- Creatinine > 1.5 mg/dL
- Total bilirubin ≤ 1.5 times normal
- Alkaline phosphatase ≤ 2.5 times normal (5 times normal if liver involvement)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients of must use effective contraception
Exclusion criteria:
- Progressive gastroduodenal ulcer, prior hemorrhagic ulcer, or perforation in the past 6 months
- Enteropathy or chronic diarrhea
- Chronic inflammatory intestinal disease
- Intestinal obstruction
Active cardiac disease including any of the following:
- Uncontrolled hypertension
- Myocardial infarction in the past 12 months
- Serious angina
- NYHA class II-IV congestive heart failure
- Severe arrhythmia (even if treated)
- Peripheral vascular disease ≥ grade 2
- Unhealed wound, ulcer, or severe bone fracture
- Bleeding disorder or coagulopathy
- Severe uncontrolled infection or medical condition
- Proteinuria > 500 mg/24 hours
- Other malignancy within the past 5 years except basal cell skin cancer or curatively treated carcinoma in situ of the cervix
- Known dihydropyrimidine dehydrogenase deficiency
- Severe traumatic injury within the past 4 weeks
PRIOR CONCURRENT THERAPY:
Inclusion criteria:
- At least 2 weeks since prior radiotherapy
Exclusion criteria:
- Prior chemotherapy for metastatic disease except adjuvant chemotherapy completed > 6 months ago
- Prior irinotecan hydrochloride or bevacizumab
- Major surgery or biopsy within the past 4 weeks
- Major surgery planned
- Puncture in the past week
- Chronic aspirin (> 325 mg/day) or NSAIDs
- Concurrent antifungal azoles (e.g., ketoconazole, fluconazole, itraconazole)
- Concurrent phenytoin (as in yellow fever vaccine)
- Concurrent Hypericum perforatum (St. John's wort)
Oral or parenteral coagulant in the past 10 days and during study therapy
- Warfarin allowed provided INR < 1.5
Contacts and Locations
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00541125 History of Changes |
| Other Study ID Numbers: | CDR0000564089, FFCD-0604, EU-20757, EUDRACT-2007-001772-37 |
| Study First Received: | October 5, 2007 |
| Last Updated: | February 6, 2009 |
| Health Authority: | Unspecified |
Keywords provided by National Cancer Institute (NCI):
|
recurrent colon cancer stage IV colon cancer recurrent rectal cancer |
stage IV rectal cancer adenocarcinoma of the colon adenocarcinoma of the rectum |
Additional relevant MeSH terms:
|
Colorectal Neoplasms Neutropenia Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Agranulocytosis Leukopenia Leukocyte Disorders |
Hematologic Diseases Fluorouracil Irinotecan Bevacizumab Camptothecin Lenograstim Leucovorin Levoleucovorin Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antimetabolites, Antineoplastic Antineoplastic Agents Therapeutic Uses Immunosuppressive Agents |
ClinicalTrials.gov processed this record on May 19, 2013